---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-098726"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-12-27T23:59:59+00:00"
generated_at: "2026-06-07T06:56:18.192252+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bluejay initiates SYMON multicenter study of Symphony IL-6 test in sepsis patients

## Summary
- Study will monitor IL-6 in sepsis/septic shock patients admitted to ICU; aims to predict 28-day mortality.
- Study design incorporates feedback from pre-submission meetings with the FDA held earlier in 2023.
- Symphony System delivers results from whole blood in ~20 minutes; study listed on clinicaltrials.gov (NCT06181604).
- CEO Neil Dey says study moves company 'one step closer to commercialization' and may identify competitive advantages.

## SEC filing metadata
- accession: 0001213900-23-098726
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023098726/0001213900-23-098726-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023098726/ea190739-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-098726
- JSON: https://secwatch.observer/filing/0001213900-23-098726.json
- Plain text: https://secwatch.observer/filing/0001213900-23-098726.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.